Extension Study of ACE-083 in FSHD and CMT

Phase 2, randomised, open-label trial of efmitermant alfa in facioscapulohumeral muscular dystrophy (FSHD), Charcot-Marie-Tooth disease type 1 (CMT1) and Charcot-Marie-Tooth disease type X (CMTX) (9 arms). Primary endpoints: Frequency of Adverse Events - Presence and Nature of Adverse Events, Frequency of Adverse Events - Presence and Nature of Grade 3 or Higher Adverse Events and 1 more. Started May 2019; status: terminated.